Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer

Molecular Therapy

Volumn 15, Issue 5, 2007, Pages 912-920

  Nguyen, Minh ^a   Huan Tu, Guang ^a   Gonzalez Edick, Melissa ^a   Rivera, Victor M ^b   Clackson, Tim ^b   Jooss, Karin U ^a   Harding, Thomas C ^a  

^a CELL GENESYS INC   (United States)

^b ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PARVOVIRUS VECTOR; RAPAMYCIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE TRANSFER; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TRANSGENE; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENO-ASSOCIATED VIRUS; MAMMALIA;

EID: 34247208499     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.sj.6300079     Document Type: Article

References (42)

1. Toniatti, C, Bujard, H, Cortese, R and Ciliberto, G (2004). Gene therapy progress and prospects: Transcription regulatory systems. Gene Ther 11: 649-657.
2. Goverdhana, S, Puntel, M, Xiong, W, Zirger, JM, Barcia, C and Curtin, JF et al. (2005). Regulatable gene expression systems for gene therapy applications: Progress and future challenges. Mol Ther 12: 189-211.
3. Pollock, R and Clackson, T (2002). Dimerizer-regulated gene expression. Curr Opin Biotechnol 13: 459-467.
4. Rivera, VM, Gao, GP, Grant RL, Schnell, MA, Zoltick, PW and Rozamus, LW et al. (2005). Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430.
5. Wang, J, Voutetakis, A, Papa, M, Rivera, VM, Clackson, T and Lodde, BM et al. (2005). Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands. Gene Ther 13: 187-190.
6. Sanftner, LM, Rivera, VM, Suzuki, BM, Feng, L, Berk, L and Zhou, S et al. (2006). Dimerizer regualation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol Ther 13 167-174.
7. Lebherz, C, Auricchio, A, Maguire, AM, Rivera, VM, Tang, W and Grant, RL et al. (2005). Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther 16: 178-186.
8. Schreiber, S L (1991). Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251: 283-287.
9. Morris, RE, Meiser, BM, Wu, J, Shorthouse, R and Wang, J (1991). Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 23: 521-524.
10. Calne, RY, Collier, DS, Lim, S, Pollard, SG, Samaan, A and White, DJ et al. (1989). Rapamycin for immunosuppression in organ allografting. Lancet 2: 227.
11. Faivre, S, Kroemer, G and Raymond, E (2006). Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Disc 5: 671-688.
12. Xing, D and Orsulic, S (2005). A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA 102: 6936-6941.
13. Guba, M, von Breitenbuch, P, Steinbauer, M, Koehl, G, Flegel, S and Homburg, M et al. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8: 128-135.
14. Moss, RB, Rodman, DM, Spencer, LT, Aitken, ML, Zeitlin, PL and Waltz, D et al. (2004). Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial. Chest 125: 509-521.
15. Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW and Arruda, VR et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972.
16. Janson, C, Mcphee, S, Bilaniuk, L, Haselgrove, J, Testaiuti, M and Freese, A et al. (2002). Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 13 1391-1412.
17. Luo, J, Kaplitt MG, Fitzsimons, HL, Zuzga, DS, Liu, Y and Oshinsky, ML et al. (2002). Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298: 425-429.
18. Berns, KI and Linden, RM (1995). The cryptic life style of adeno-associated virus. Bioessays 17: 237-245.
19. Grimm, D and Kay, MA (2003). From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3: 281-304.
20. Jooss, K, Yang, Y, Fisher, KJ and Wilson, JM (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72: 4212-4223.
21. III, CR, Yang, CQ, Bidlingmaier, SM, Gonzales, JN, Burns, DS and Bartholomew, RM et al. (1997). Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. Blood Coagul Fibrinolysis 8 (Suppl 2): 523-530.
22. O'Reilly, MS, Holmgren, L, Chen, C and Folkman, J (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692.
23. Lalani, AS, Chang, B, Lin, J, Case, SS, Luan, B and Wu-Prior, WW et al. (2004). Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. Mol Ther 9 56-66.
24. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859.
25. Holash, J, Davis, S, Papadopoulos, N, Croll, SD, Ho, L and Russell, M et al. (2002). VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99; 11393-11398.
26. Harding, TC, Lalini, AS, Roberts, BN, Yendluri, S, Laun, B and Koprivnikar, KE et al. (2006). AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol Their 13: 956-966.
27. Rivera, VM, Ye, X, Courage, NL, Sachar, J, Cerasoli Jr, F and Wilson, JM et al. (1996). Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci USA 96: 8657-8662.
28. Ye, X, Rivera, VM, Zoltick, P, Cerasoli Jr, F, Schnell, MA and Gao, G et al. (1999). Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283: 88-91.
29. Johnston, J, Tazelaar, J, Rivera, VM, Clackson, T, Gao, GP and Wilson, JM (2003). Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model. Mol Ther 7: 493-497.
30. Mizuguchi, H, Xu, Z, Ishii-Watabe, A, Uchida, E and Hayakawa, T (2000). IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1: 376-382.
31. Hennecke, M, Kwissa, M, Metzger, K, Oumard, A, Kroger, A and Schirmbeck, R et al. (2001). Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res 29: 3327-3334.
32. Harries, M, Phillipps, N, Anderson, R, Prentice, G and Collins, M (2000). Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout. J Gene Med 2: 243-249.
33. Zhou, Y, Aran, J, Gottesman, MM and Pastan, I (1998). Co-expression of human adenosine deaminase and multidrug resistance using a blcistronic retroviral vector. Hum Gene Ther 9: 287-293.
34. Borman, AM, Le Mercier, P, Girard, M and Kean, KM (1997). Comparison of picomaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res 25: 925-932.
35. Roberts, LO, Seamons, RA and Belsham, GJ (1998). Recognition of picomavirus internal ribosome entry sites within cells; influence of cellular and viral proteins. RNA 4: 520-529.
36. Geoerger, B, Kerr, K, Tang, CB, Fung, KM, Powell, B and Sutton, LN et al. (2001). Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61: 1527-1532.
37. Reardon, D, Friedman, H, Yung, WKA, Brada, M, Conrad, C and Provenzale, J et al. (2004). A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 22 (14S) abstr 1513.
38. Yung, WKA, Friedman, H, Jackson, E, Provenzale, J, Leeds, N and Conrad, C et al. (2002). A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc Am Soc Clin Oncol 21, abstr 315.
39. Goudar, RK, Shi, Q Hjelmeland, MD, Keir, ST, McLendon, RE and Wikstrand, CJ et al. (2005). Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4: 101-112.
40. Auricchio, A, Rivera, VM, Clackson, T, O'Connor, EE, Maguire, AM and Tolentino, MJ et al. (2002). Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 6: 238-242.
41. Costa, RH, Lai, E, Grayson, DR and Darnell Jr, JE (1988). The cell-specific enhancer of the mouse transthyretin (prealbumin) gene binds a common factor at one site and a liver-specific factor(s) at two other sites. Mol Cell Biol 8: 81-90.
42. Xiao, X, Li, J and Samulski, RJ (1998). Production of high-titer recombinant adeno-associated virus vectors in them absence of helper adenovirus. J Virol 72: 2224-2232.